Showing results (171-180 of 219) with videos related to

Sort By:
Pageof 22
Nature Reviews. Clinical Oncology|September 20, 2017
Chimeric antigen receptor T-cell therapy - assessment and management of toxicitiesSattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylateHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
American Journal of Hematology|November 5, 2019
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survivalMusa Yilmaz, Hagop Kantarjian, Xuemei Wang, et al.
The Lancet. Haematology|May 15, 2023
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trialElias Jabbour, Nicholas J Short, Jayastu Senapati, et al.
Cancer|July 21, 2021
Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphomaBei Hu, Danielle Boselli, Lisa M Pye, et al.
The Lancet. Oncology|October 4, 2015
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 studyElias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignanciesKaren W L Yee, Anne Hagey, Srdan Verstovsek, et al.
The Lancet. Oncology|January 21, 2018
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 studyHagop Kantarjian, Farhad Ravandi, Nicholas J Short, et al.
Frontiers in Immunology|January 31, 2018
The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by LenalidomideHila Shaim, Zeev Estrov, David Harris, et al.
British Journal of Haematology|October 23, 2015
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemiaFarhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
Pageof 22